Pressure BioSciences Pitch Deck Teardown: A Public Life

Pressure BioSciences: The 2017 Investor Deck Analysis

Pressure BioSciences, Inc. (OTCQB: PBIO) operates in the highly specialized niche of biological sample preparation. Their March 2017 investor presentation is a classic example of a life sciences deck that prioritizes technical validation and academic endorsement over the flashy growth metrics often seen in software pitches. The company aims to solve the 'bottleneck' of sample preparation, which they argue is the most critical step in the discovery of new biomarkers.

Slide 1: Title and Positioning

The cover slide establishes the company as a public entity (OTCQB: PBIO) and introduces the tagline: "Discovery Starts with Sample Preparation." This is a strategic choice; by positioning themselves at the very beginning of the research workflow, they argue that their technology is a prerequisite for all subsequent discovery work. The presentation is attributed to Richard T. Schumacher, the Founder, President, and CEO.

Slide 4: Experienced Senior Management & Board

This slide is heavy on credentials, which is vital for a biotech company. CEO Richard Schumacher’s history with Boston Biomedica and Trinity Biotech suggests a track record in the industry. The inclusion of Dr. Edmund Y. Ting (Senior VP of Engineering) is notable for his background at Avure Technologies and Flow International, companies known for high-pressure processing. The board section lists specific committee chairs (Audit, Compensation, SAB), signaling a structured corporate governance expected of a public company.

Slide 7: The Value Proposition

Slide 7 serves as the executive summary of the company's market thesis. It makes several bold claims:

Analysis of biomolecules is crucial to biomarker discovery, and quality depends on preparation. · The market is estimated at 500,000 scientists in 80,000 labs. · Current mechanical methods are labeled a "Bottleneck." · The platform is "Proven" with ~275 systems installed across ~150 sites. · 100+ publications support their claims.

This slide effectively combines the problem (inadequate preparation), the solution (PCT), and the traction (install base and publications) into a single view.

Slide 10: PCT Sample Preparation System

This is the product slide. It displays the hardware lineup, including the Barocycler NEP2320 and the "Just Released" Barocycler 2320 EXTREME. Crucially, it also shows the consumables: PULSE Tubes, MicroTubes, and PCT-dependent Kits. For an investor, this slide represents the revenue engine. The variety of tubes and kits suggests a recurring revenue model where the sale of one Barocycler leads to years of consumable purchases.

Slide 13: Biomarker Discovery Validation

To prove the efficacy of their high-pressure approach, the company uses a case study from Professor Jennifer Van Eyk at Cedars-Sinai Medical Center. The slide focuses on FFPE (formalin-fixed paraffin-embedded) samples, noting there are over 1 billion such samples archived. The "Conclusion" section states that the combination of heat and elevated pressure increased protein yield, making rare samples "invaluable" for discovery. This targets a specific, massive pain point in pathology: extracting usable data from old, preserved tissue.

Slide 16: Personalized Medicine and Proteome Maps

The deck moves from general research to the high-growth area of personalized medicine. Featuring Professor Ruedi Aebersold of ETH Zurich, the slide discusses "PCT-SWATH." The claim here is that the technology can convert tissue biopsies into "permanent quantitative digital proteome maps." By citing Nature Medicine (March 2015), the company leverages the highest level of peer-reviewed credibility to suggest that clinical adoption is the ultimate trajectory for the technology.

Slide 19: The CMRI Alliance and Cancer Moonshot

This slide provides a concrete example of large-scale commercial and clinical application. The alliance with the Children’s Medical Research Institute (CMRI) in Australia is linked to the US Cancer Moonshot initiative. The metrics provided are specific: CMRI will test 70,000 tumor samples and has purchased 3 Barocyclers plus consumables. The quote from Dr. Phil Robinson emphasizes that PCT allows for the analysis of samples as small as those provided by needle biopsies, which is a significant technical advantage in clinical settings.

What Works in This Deck

Third-Party Validation: The deck relies heavily on external experts. By featuring professors from Cedars-Sinai and ETH Zurich, Pressure BioSciences lets the customers do the selling. This is highly effective in scientific sectors where a founder's claims are viewed with skepticism until verified by the academic community.

Clear Problem Identification: Identifying sample preparation as a "bottleneck" (Slide 7) is a strong narrative hook. It frames the company not just as a hardware manufacturer, but as a solution to a systemic delay in the multi-billion dollar life sciences industry.

Product Breadth: Slide 10 clearly shows that this is a complete ecosystem. Investors can see the hardware, the specialized containers (PULSE tubes), and the chemical kits, which points toward a sustainable business model beyond one-off equipment sales.

What Is Missing from This Deck

Financial Transparency: As a public company, one might expect a summary of recent quarterly performance or a revenue growth chart. The deck is entirely silent on the company's actual financial health, revenue figures, or burn rate. While these are in SEC filings, their absence here makes it difficult to assess the business's commercial momentum.

Competitive Landscape: The deck mentions that current methods are "mostly mechanical," but it does not name competitors or provide a head-to-head comparison on cost, speed, or yield. Investors are left to wonder who else is trying to solve the sample prep bottleneck and how PBIO's patents hold up against them.

The "Ask": There is no slide detailing what the company is looking for from investors. Is this a pitch for a specific PIPE (Private Investment in Public Equity) deal? Is it a general awareness deck? Without a clear "Ask" or "Use of Funds" slide, the presentation feels more like a technical briefing than a fundraising tool.

Founder's Guide: What to Copy

The Case Study Format: Slides 13 and 16 are excellent templates for technical founders. Instead of just listing features, they show a photo of a high-profile user, list their credentials, state the specific problem they faced (e.g., low yield from FFPE samples), and provide the validated conclusion. This builds trust far faster than a list of specs.

Linking to Macro Trends: Slide 19 successfully hitches the company's wagon to a major government initiative (The Cancer Moonshot). If your startup aligns with a major national or global priority, make that connection explicit. It provides a sense of urgency and scale that internal metrics alone cannot convey.

Visualizing the Ecosystem: Slide 10 is a great example of how to show a complex product line. By grouping the main unit with its necessary accessories and consumables, the company visually communicates its entire value chain in one glance. Founders with a "razor/blade" model should always include a slide that shows both the razor and the blades together.